Matrix metalloproteinases (MMPs) 2 are a family of by either acrylamide or iodide is significantly in-zinc-dependent proteinases which function in the degcreased following mercurial activation. In contrast, no radation of collagen and other extracellular matrix significant change in tryptophan accessibility accom-macromolecules [reviewed in (1)]. Included in the MMP panies mercurial treatment of either proMMP-2 or family are interstitial collagenase (MMP-1), gelatinase TIMP-2 alone, or mercurial-activated MMP-2 mixed A (MMP-2), gelatinase B (MMP-9), and stromelysin-1 with TIMP-2. To determine whether the enhanced flu-(MMP-3). ProMMP-2 is purified in tight complex with orescence quenching was unique to the activated tissue inhibitor of metalloproteinases (TIMP)-2 (desigproMMP-2/TIMP-2 complex, similar experiments were nated proMMP-2/TIMP-2), while proMMP-9 copurifies performed using MMP-1, MMP-3, and MMP-9/TIMP-1 in a stable stoichiometric complex with TIMP-1 (desigcomplex. In all cases, both latent and mercurial-nated proMMP-9/TIMP-1) [for a review, see (2) 
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domain, the metal binding catalytic domain, and the TIMP-2 complex upon activation by a mercurial compound. COOH-terminal domain (1, 3) . The NH 2 -terminal domain contains an highly conserved sequence PRCG-[V/N]PD, the cysteine residue of which is proposed to EXPERIMENTAL coordinate with the zinc atom in the active site metal MMP purification and activation. ProMMP-2/TIMP-2 complex binding domain, thereby maintaining latency of the zy-and proMMP-2 free of TIMP-2 were purified from the conditioned mogen (4-7). The COOH-terminal domain contains an medium of human uterine cervical fibroblasts by gelatin-Sepharose affinity chromatography and gel permeation chromatography on hemopexin-like region which is involved in regulation Sephacryl S-200 as previously described (23). The purified proMMPof substrate specificity for some members of the MMP 2/TIMP-2 was free of uncomplexed proMMP-2 or TIMP-2 as confamily (8) . Both MMP-2 and MMP-9 contain a domain firmed by the loss of MMP inhibitory activity of TIMP-2 and the lack with similarity to the type II domain of fibronectin, of gelatinolytic activity of MMP-2 upon treatment of the complex whereas MMP-9 has an additional collagen-like inser-with 1 mM 4-aminophenylmercuric acetate. TIMP-2 was purified by dissociation of the proMMP-2/TIMP-2 complex with 8 M urea and 20 tion (9, 10) . ProMMP-2 and proMMP-9 form complexes mM EDTA. The resulting proMMP-2 and TIMP-2 were separated by with TIMP-2 and TIMP-1, respectively, through an ingel permeation chromatography on Sephacryl S-200 equilibrated teraction involving the C-terminal domains of both the with 50 mM Tris-HCl, pH 7.5, containing 8 M urea, 10 mM EDTA, gelatinases and the TIMPs (11-15).
1 M NaCl, and 0.02% NaN 3 . TIMP-2-containing fractions were conThe extracellular activity of MMPs is regulated in part centrated, dialyzed against 50 mM Tris-HCl, pH 7.5, containing 0.4 M NaCl, 10 mM CaCl 2 , 0.02% NaN 3 (TNC buffer) and rechromatoby secretion as inactive proenzymes. MMP zymogens can graphed on Sephacryl S-200 equilibrated with TNC buffer. The conbe converted to active enzymes in vitro by treatment with centration of TIMP-2 was calculated by titration with a known chaotropic and organomercurial reagents or by limited amount of MMP-3. ProMMP-1 and proMMP-3 were purified from proteolytic cleavage (4, 16, 17) . Activation is thought to the conditioned medium of human rheumatoid synovial fibroblasts proceed via disruption of the interaction between the un-as described previously (18, 24, 25) . ProMMP-9/TIMP-1 was purified from the conditioned medium of U937 monocytic leukemia cells (26) . paired cysteine residue in the amino-terminal propeptide Latent MMPs were activated by incubation with 1 mM HgCl 2 at and the active site zinc atom (4, 5) . It has been proposed 37ЊC for 1 h followed by chromatography on prepacked Sephadex that an initial step in proMMP activation by nonproteo-G-25 gel filtration columns (PD10, Pharmacia, Piscataway, NJ) to lytic agents involves the induction of a conformational remove HgCl 2 . TIMP-2 was also treated with HgCl 2 as described above. ProMMPs and TIMP-2 (not treated with mercurial) were also change in the zymogen which then results in autocataapplied to PD10 columns under identical conditions. In addition, lytic cleavage of the proenzyme and bimolecular proproMMPs and TIMP-2 were denatured by incubation for 18 h at cessing to the fully active mature enzyme (5, (16) (17) (18) (19) . room temperature in 6.7 M guanidine-HCl (21) followed by chromaTo investigate further the possibility of conformational tography on PD10 equilibrated with 6.7 M guanidine-HCl. alterations in MMPs upon activation, we examined the Fluorescence measurements. Steady state fluorescence measureaccessibility of tryptophan residues using fluorescence ments were performed using a Shimadzu RF-540 spectrofluorometer with temperature maintained constant at 25ЊC using a refrigerated quenching agents.
circulating water bath. An excitation wavelength of 295 nm was Intrinsic fluorescence emission of tryptophan residues used to minimize interference from tyrosine groups, emission was in a protein provides a sensitive probe of structural prop-monitored in the range of 300-400 nm (using 5 nm excitation and erties of the protein microenvironment [for reviews, see emission slit widths), and spectra were corrected for buffer blank. be used to probe the relative exposure of fluorescent resior iodide (0-0.2 M) in a total volume of 500 ml. In iodide quenching dues in proteins under a specified set of conditions. Two experiments, constant ionic strength was maintained using NaCl. In commonly used quenching agents are acrylamide and addition, the KI stock solution contained 0.1 M Na 2 S 2 O 3 to prevent iodide, both of which function through collision with the formation of I agent. Acrylamide is a polar nonionic quencher which fluorescence intensities were corrected for the attenuation of the excan penetrate the protein surface, whereas iodide is a citing light intensity due to absorption by acrylamide (21) . With both large polar anion with access to only surface Trp residues iodide and acrylamide, no large changes in the wavelength of maximal fluorescence were observed at any quencher concentration, indi- (21, 22) . In this study, we have utilized both acrylamide cating the absence of protein denaturation (27). The initial aband iodide as quenchers to probe conformational altersorbance of protein solutions was less than 0.1 at the excitation ations in MMPs which may accompany zymogen activa-wavelength to avoid the inner filter effect (4). Experimental error in tion and report that fluorescence quenching of the fluorescence measurements was estimated to be less than 5%. proMMP-2/TIMP-2 complex is significantly increased folFluorescence data were analyzed using the Stern-Volmer equation for steady state collisional quenching: lowing mercurial activation, whereas both latent and mercurial-treated MMP-1, MMP-2, MMP-3, MMP-9/
TIMP-1, and TIMP-2 exhibit similar fluorescence quench profiles. These data provide biophysical evidence for a significant structural rearrangement of the proMMP-2/ where F 0 is the fluorescence intensity in the absence of quencher, F is in the properties of intrinsic protein fluorescence are expected, including a change in the wavelength of maximum emission and/or altered susceptibility to quenching agents. Therefore, monitoring intrinsic fluorescence of MMPs and quantitation of the relative abilities of acrylamide and iodide to quench Trp fluorescence in either the proenzyme or active form should enable detection of conformational alterations of the enzyme upon activation. A representative fluorescence emission spectrum is shown in Fig. 1 . A progressive decrease in Trp fluorescence was observed upon addition of quenching agent to MMPs-1, -2, -3, MMP-2/TIMP-2 and MMP-9/TIMP-1. At the highest concentration of quenching agent added (0.2 M iodide, 0.5 M acrylamide), fluorescence quenching ranged from 13.1-43.8% with iodide, whereas acrylamide resulted in a greater overall decrease in protein fluorescence, with quenching ranging from 25.9 to 63.9% (Table I) . Data for MMPs unfolded by treatment with 6.7 M guanidine-HCl are included for comparison. These data indicate that MMP fluorescence is more efficiently quenched by acrylamide than iodide, suggesting that most, if not all Trp residues are not localized on the protein surface. This is supported in part by the conserved location of most Trp residues in the  FIG. 1 . Fluorescence emission spectrum of proMMP-2. ProMMP-2 MMP family. Alternatively, the presence of amino acids was diluted to a final concentration of 100 nM in 20 mM Hepes, with negatively charged side chains in the vicinity of Data obtained for acrylamide quenching of the proen-population of Trp residues with unequal accessibility to quencher. Comparison of the proenzyme (circles) and zyme, active, and guanidine-treated forms of MMPs-1, -2, and -3 were analyzed by the Stern-Volmer equa-activated (triangles) forms of MMPs-1, -2, and -3 indicates that little change in Trp accessibility to either tion and are shown in Figs. 2A-2C , respectively. In several cases, downward curvature of the Stern-acrylamide (Fig. 2) or iodide (data not shown) accompanies activation. In contrast, guanidine unfolding reVolmer plots is observed, indicative of greater than one sults in increased solute quenching of Trp fluorescence ever we cannot rule out the possibility that a conformational change does occur which does not alter the sol-(squares). These data suggest that the active conformations of MMPs-1, -2, and -3 are not significantly differ-vent accessibility of any MMP Trp residues or, alternatively, that compensatory changes in Trp environments ent than the proenzyme forms. This is in agreement with X-ray crystallographic data which indicate little occur.
In contrast to results obtained with free MMPs, the overall conformational change in the catalytic domain of proMMP-3 as a consequence of activation (29) . How-proMMP-2/TIMP-2 complex exhibits significant en- a Latent (pro), HgCl 2 -treated, or guanidine-hydrochloride-treated (GuHCl) MMPs were prepared as described under Experimental. Fluorescence was determined using an excitation wavelength of 295 nm and monitoring emission in the range of 300-400 nm. Fractional accessibilities (f a ) and quench constants (K Q ) were calculated using the modified Stern-Volmer equation as described under Experimental.
b These values were obtained with the complex between HgCl 2 -treated proMMP-2 and TIMP-2.
hancement in fluorescence quenching by both acryl-rearrangement of the activated complex. This observation is in agreement with our recent biochemical studamide (Fig. 3A) and iodide (data not shown) upon activation, indicating an activation-induced change in the ies which also predict a considerable structural rearrangement of the proMMP-2/TIMP-2 complex following accessibility of Trp residue(s) to quenching agent. This enhanced quenching is reflected by the increased frac-activation by a mercurial compound, 4-aminophenylmercuric acetate (23). In this report, we demonstrated tional accessibility ( f a ) of Trp in the HgCl 2 -treated complex, similar to that observed with guanidine-treated that mercurial treatment of proMMP-2/TIMP-2 induces a conformational perturbation which triggers proMMP-2/TIMP-2 (Table II) , and suggests that a previously buried Trp residue(s) becomes available to sol-disruption of the Cys 75 -Zn 2/ interaction in proMMP-2. The exposed active site then rapidly interacts with and vent. A relatively small increase in the quench constant (K Q ) is observed with guanidine-treated proMMP-2/ is inhibited by the NH 2 -terminal domain of TIMP-2 prior to propeptide autoprocessing, resulting in the for-TIMP-2, suggesting that although more Trp residues are available to acrylamide in the guanidine-treated mation of an ''activated proMMP-2/TIMP-2'' complex.
This structural rearrangement is supported by the obprotein, it is more difficult to quench their fluorescence (22). In contrast, the K Q of HgCl 2 -treated MMP-2/ servation that the proMMP-2/TIMP-2 complex can inhibit other active MMPs, while the activated complex TIMP-2 approaches that of free Trp in solution (17.5 (Fig. 3C, Table II ). Together these data suggest that a conformational rearrangement in MMP-nously added proMMP-2 and TIMP-2, relative to that of proMMP-2 alone or TIMP-2 alone, would be predicted. 2/TIMP-2 accompanies mercurial treatment of the complex. This phenomenom appears to be unique to the However, no large changes in fractional accessibility were observed (Table II) . These data suggest that the proMMP-2/TIMP-2 complex, as quenching experiments with the MMP-9/TIMP-1 complex showed no differ-fluorescence changes associated with mercurial treatment of the proMMP-2/TIMP-2 complex likely reflect ences in fluorescence parameters between latent and mercurial-activated complex (Fig. 2D) . a novel structure in the complex between the ''activated proMMP-2'' (containing the propeptide) and TIMP-2. In summary, using fluorescence quenching analysis as a conformational probe, no significant change in Trp Such a structure is not formed in the case of the proMMP-9/TIMP-1 complex, as the propeptide of environment is detectable following zymogen activation of proMMPs-1, -2, -3 and proMMP-9/TIMP-1. How-proMMP-9 in this complex is removed upon mercurial activation (28). The conformation of proMMP-2 which ever, activation of proMMP-2/TIMP-2 does result in increased accessibility of previously buried Trp resi-is trapped in the activated complex may be representative of a transitional structure induced in proMMP-2 due(s), providing biophysical evidence for a structural
